Limitations, agreements, and source contact

Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer · Source last updated 2021-09-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restriction Type

LTE60

restrictive Agreement

true

point Of Contact

email

Linda.Gedeon@roswellpark.org

organization

NRG Oncology

phone

716-845-1169

title

Linda Gedeon on behalf of Virginia Filiaci, PhD.

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice